GLP-1 Receptor Agonists for Opioid Use Disorder
GLP-1 receptor agonists show promising evidence for reducing opioid use disorder-related outcomes and should be considered as an emerging adjunctive treatment option, particularly in patients with comorbid type 2 diabetes or obesity, though they are not yet FDA-approved for this indication.
Current Evidence Base
Real-World Clinical Data
The strongest real-world evidence comes from a large retrospective cohort study analyzing over 500,000 patients with opioid use disorder, which demonstrated that GLP-1RA prescriptions were associated with a 40% reduction in opioid overdose rates (adjusted incidence rate ratio 0.60; 95% CI 0.43-0.83) compared to patients without such prescriptions 1. This protective effect remained consistent across subgroups, including those with and without comorbid type 2 diabetes or obesity 1.
In older adults (≥65 years) with coexisting type 2 diabetes and substance use disorders, GLP-1RA initiators showed a 24% lower risk of substance use disorder-related hospitalization and a 36% lower risk of opioid use disorder-specific hospitalization compared to DPP-4 inhibitor users 2.
Preclinical Mechanisms
The mechanistic basis for GLP-1RAs in opioid use disorder involves modulation of the mesolimbic reward system:
A novel GLP-1R/Y1/Y2 triple agonist (GEP12) reduced fentanyl-evoked dopamine release in the nucleus accumbens and decreased both fentanyl taking and seeking behaviors in rats at doses that were well-tolerated without producing malaise-like effects 3.
Exendin-4, a GLP-1R agonist, reduced both cue-induced and drug-induced reinstatement of heroin-seeking behavior in rats, with associated increases in Orexin 1 receptor expression in the nucleus accumbens shell 4.
These agents appear to work by modulating neuroinflammation, neurotransmitter systems, and reward pathways centrally 5.
Clinical Application Algorithm
Patient Selection
Prioritize GLP-1RA consideration in patients with opioid use disorder who have:
- Comorbid type 2 diabetes (FDA-approved indication) 1, 2
- Comorbid obesity (FDA-approved indication) 1, 2
- History of recurrent opioid overdoses 1
- Failed or inadequate response to standard medications for opioid use disorder (methadone, buprenorphine, naltrexone) 6
Integration with Standard Treatment
GLP-1RAs should be used as adjunctive therapy, not as replacement for evidence-based medications for opioid use disorder (methadone, buprenorphine, or naltrexone), which remain the guideline-recommended first-line treatments 6. The systematic review of MOUD access emphasizes that existing clinical guidelines recommend these standard medications, and GLP-1RAs represent an emerging complementary approach 6.
Agent Selection
Based on current trial activity, semaglutide and tirzepatide are the most studied next-generation agents for substance use disorders, with 15 and 6 ongoing trials respectively 7. Older agents like exenatide and liraglutide have more preclinical data but fewer active clinical trials 4, 7.
Important Caveats
Regulatory Status
No GLP-1RA is currently FDA-approved for opioid use disorder treatment 7. Use for this indication represents off-label prescribing, which is appropriate when prescribed for comorbid diabetes or obesity with the understanding of potential substance use benefits 1, 2.
Evidence Gaps
- Most clinical trials focus on alcohol and nicotine use disorders, with only 4 registered trials specifically targeting opioid use disorder 7
- Studies use heterogeneous outcome measures mixing self-report with objective indices 7
- Long-term safety and efficacy data in opioid use disorder populations are limited 5
Timing Considerations
The exendin-4 study showed that pretreatment timing matters: drug-induced heroin seeking was reduced with 1-hour but not 6-hour pretreatment intervals 4. This suggests that for acute craving management, timing of GLP-1RA administration relative to high-risk situations may be relevant.
Access Barriers
Be aware that adolescents and young adults face significant barriers to accessing any medications for opioid use disorder, with disparities based on criminal justice involvement, geographic location (US South), income level, and race/ethnicity 6. These same barriers may affect GLP-1RA access, compounded by high medication costs.